Trials / Completed
CompletedNCT00534638
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 34,412 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years – 15 Years
- Healthy volunteers
- Accepted
Summary
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cervarix | Intramuscular injection, 3 doses |
| BIOLOGICAL | Engerix-B | Intramuscular injection, 3 doses |
Timeline
- Start date
- 2007-10-04
- Primary completion
- 2014-12-17
- Completion
- 2014-12-17
- First posted
- 2007-09-26
- Last updated
- 2019-11-15
- Results posted
- 2016-01-26
Locations
6 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT00534638. Inclusion in this directory is not an endorsement.